GetTopicDetailResponse(id=6d1912e18776, topicName=坦昔妥單抗, introduction=, content=DLBCL 坦昔妥單抗, image=null, comments=0, allHits=229, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Thu May 22 20:36:25 CST 2025, time=2025-05-22, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=504851, tagList=[TagDto(tagId=504851, tagName=坦昔妥單抗)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2266252, encodeId=f81d22662522f, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a> <a href='/topic/show?id=6d1912e18776' target=_blank style='color:#2F92EE;'>#坦昔妥單抗#</a>, objectTitle=坦昔妥單抗聯(lián)合來那度胺治療R/R DLBCL的真實世界研究, objectType=article, longId=878604, objectId=155a8e8604f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220813/1660373278819_8252897.webp, objectUrl=/article/show_article.do?id=155a8e8604f4, replyNumber=0, likeNumber=24, createdTime=2025-05-22, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=155a8e8604f4, moduleTitle=坦昔妥單抗聯(lián)合來那度胺治療R/R DLBCL的真實世界研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=155a8e8604f4)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-05-22發(fā)表于上海
